The FDA has granted Priority Review for Nexavar (sorafenib) tablets in the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.

Nexavar's side effects don't seem to be worse than Avastin's. Considering their is no Black Box warning on Nexavar, one might be able to conclude that Nexavar could be safer and more tolerable. It ...

Mar. 23 -- MONDAY, Nov. 19 (HealthDay News) -- The Bayer anticancer drug Nexavar (sorafenib) has been approved by the U.S. Food and Drug Administration to treat the most common form of liver ...

Despite these issues, Reddoch thinks Nexavar will benefit from the liver-cancer study findings. He raised his forecast for U.S. liver-cancer sales for Nexavar from $72 million to $187 million in 2010.

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals Inc. today announced that Nexavar (sorafenib) tablets significantly extended overall survival in patients with hepatocellular ...

The sNDA submission, completed in June 2007, was based on data from thePhase 3 SHARP trial which demonstrated that Nexavar extended overall survivalby 44 percent in patients with HCC (HR=0.69; p=0 ...

Nexavar is a prescription drug used to treat liver, kidney, and thyroid cancers. Learn about the drug's dosage, form, strength, how to take it, and more.

Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday.

Nexavar Works for Liver Cancer, But It Isn’t Cheap. Share. Resize. This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber ...

Bayer is arguing that it did not steal an analog of its Nexavar cancer drug from development partner Onyx because, in part, Onyx got the name of the analog wrong in its lawsuit.Onyx sued Bayer in ...

Breast Cancer Trial Design and Results. The randomized, double-blind, placebo-controlled Phase II study evaluated Nexavar in combination with the oral chemotherapeutic agent, capecitabine, in 229 ...

Bayer's cancer drug Nexavar was given priority review status by U.S. healthcare regulators for the oral drug's use against a difficult-to-treat type of thyroid cancer, the company said on Tuesday.